AbbVie, Genmab announce late-stage trial setback for lymphoma therapy
Seeking Alpha ·
AbbVie ( ABBV ) and Genmab ( GMAB ) announced that their jointly developed bispecific antibody epcoritamab, marketed as Epkinly in the U.S., failed to meet the primary endpoint in a late-stage trial for patients with diffuse large B-cell lymphoma.
AI 시장 분석
AbbVie and Genmab announced that their co-developed bispecific antibody Epcoritamab failed to meet the primary efficacy endpoint in a late-stage clinical trial for patients with diffuse large B-cell lymphoma. This clinical failure makes a setback in the drug's label expansion strategy inevitable, raising concerns over a decline in the value of both companies' related pipelines. Investors should exercise caution regarding short-term stock volatility in related pharmaceutical stocks and closely monitor clinical results of subsequent pipelines.
하락 영향
- Biotechnology — Investor sentiment in the pharmaceutical and biotech sector has weakened as the failure of the late-stage clinical trial for AbbVie and Genmab's lymphoma treatment led to a decline in the drug's value.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 64% · Bearish (Short) 36%
316 participants
Related News
- Ondas, RSE invests in FPF Defense to expand low-cost counter-drone tech
- DigitalOcean closes private repurchase of about $472M of convertible senior notes due 2030
- 센시언트 테크놀로지스 주가, 오늘 급등하는 이유는?
- Amkor Jumps on $1.5 Billion Nvidia Packaging Deal
- AI 인프라 확장·헬리오스 출시에 AMD 목표주가 상향
- Tesla Selloff Hands Bears Big Gains
